Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

Latest Financial Results

Q2 2018

Quarter Ended Jun 30, 2018

Latest 10-K

Fiscal Year Ended Dec 31, 2017

View Latest 10-K

Stock Information

Company Overview

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugate™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC™ platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations.

Investor Presentation

Investor Presentation

Download Investor Presentation

Leadership

Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information

Company

Cellectar Biosciences, Inc.
8383 Greenway Blvd, Suite 600
Middleton, WI 53562
T: 608-441-8120
F: 608-441-8121
investors@cellectar.com

Investor Relations

LHA Investor Relations
Miriam Weber Miller
T: 212-838-3777
MMiller@lhai.com

Transfer Agent

American Stock Transfer
Tamara Cajuste
Relationship Manager
6201 15th Avenue
Brooklyn, NY 11219
T: 718-921-8300 ext. 6462
M: 347-939-9659
F: 718-765-8712
tcajuste@astfinancial.com

Market Data copyright © 2018 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.